newsfilter
← Latest News
GlobeNewswire·

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting